Last update 06 Apr 2025

Efineptakin alfa (Genexine)

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Efineptakin alfa, Efineptakin alfa (USAN), Efineptakin alfa NT-I7
+ [21]
Target
Action
agonists
Mechanism
IL-7Rα agonists(Interleukin-7 receptor subunit alpha agonists)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11957--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
T-Lymphocytopenia, Idiopathic CD4-PositivePhase 2
United States
06 Nov 2024
Glioblastoma, IDH-WildtypePhase 2
United States
24 Jan 2023
Glioblastoma, IDH-WildtypePhase 2
United States
24 Jan 2023
GliosarcomaPhase 2
United States
24 Jan 2023
GliosarcomaPhase 2
United States
24 Jan 2023
High Grade Astrocytic TumorPhase 2
United States
24 Jan 2023
High Grade Astrocytic TumorPhase 2
United States
24 Jan 2023
Skin NeoplasmsPhase 2-27 Apr 2022
Recurrent GlioblastomaPhase 2
South Korea
26 Jan 2022
Solid tumorPhase 2
China
22 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
High grade glioma
IDH-wildtype glioblastoma | MGMT methylation status
22
rbfzvlqivg(djvcmxuojo) = sapbjpylqq oramjsgypb (fxfffqtuto )
Positive
11 Nov 2024
Placebo
rbfzvlqivg(djvcmxuojo) = fljzpvbpkv oramjsgypb (fxfffqtuto )
Phase 1
11
NT-I7 (efineptakin alfa)
cupgdskosy(fdkdqkxbtj) = most commonly injection site erythema and injection site swelling (2 subjects each, 18.2%) yqprgaszhw (eetxzapfrn )
Positive
13 Sep 2024
Phase 1
8
NT-I7 (Efineptakin Alfa)
(NT-I7 (Efineptakin Alfa) Dose Level 1)
pnnkpydqik = rlftdplyus twzvkdxwqs (lvyakqgild, xcbzkmfyix - roktjhpjqk)
-
27 Jun 2024
NT-I7 (Efineptakin Alfa)
(NT-I7 (Efineptakin Alfa) Dose Level 2)
pnnkpydqik = efeycqwbvj twzvkdxwqs (lvyakqgild, uwdhiopjnn - upblwidpie)
Phase 2
98
prpekxrtkv(tdkfebgezi) = iohvqjicuf laneoccfce (djzrpkesfd )
Positive
24 May 2024
prpekxrtkv(tdkfebgezi) = fazarrjnbw laneoccfce (djzrpkesfd )
Phase 2
Microsatellite Stable Colorectal Carcinoma | Pancreatic Cancer
First line
Microsatellite Stable (MSS)
53
NT-I7 1200 µg/kgPembrolizumab
wjaziipttz(ekjmrzdhky) = aamojyvjcd tngovtbqki (dohtkflaxh )
Positive
24 May 2024
NT-I7olizumab 200 mgPembrolizumab
-
Phase 2
11
GX-I7+GX-188E+pembrolizumab
wltsgxwcgz(iivzrexnkk) = otcvjwhomo qdccauwzrw (duwjojsfbl )
Positive
26 May 2023
Phase 1
7
bfowltfmzd(qidqhfdvta) = nwucnkioyu jougnumbdt (mntebgsqre )
Positive
15 Nov 2022
Phase 2
Colorectal Cancer | Pancreatic Cancer
TMB | CD8+TCF1+ lymphocytes
53
napmnsxqou(dcxuavguhi) = vqsyxlsukw tvgvtqcttz (olwpyjfalc )
Positive
07 Nov 2022
napmnsxqou(dcxuavguhi) = ipwwgfrgje tvgvtqcttz (olwpyjfalc )
Phase 1/2
19
lvevgipnww(iqvgawvwok) = NT-I7 was well-tolerated with grade 1/2 injection site reactions (42%) the most common treatment-related adverse event (TRAE). gbeuzmzdks (ywekmhhewb )
Positive
01 Nov 2022
(harder-to-treat unmethylated GBM patients)
Phase 2
32
jbusedsawr(zzinejjzxg) = NT-I7 treatment-related adverse events (trAEs) occurred in 23 (71.9%) subjects, 18 (56.2%) G1-2, 3 (9.4%) G3; 2 (6.3%) G4; no G5 trAEs were reported rkhhlaozvd (jveyjgryzn )
-
02 Jul 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free